Scilex Holding Company (SCLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scilex Holding Company (SCLX) has a cash flow conversion efficiency ratio of -0.046x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.23 Million) by net assets ($-179.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Scilex Holding Company - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Scilex Holding Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Scilex Holding Company balance sheet liabilities for a breakdown of total debt and financial obligations.
Scilex Holding Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scilex Holding Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Theralase Technologies Inc.
V:TLT
|
-0.629x |
|
Eltek Ltd
NASDAQ:ELTK
|
0.044x |
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
0.007x |
|
Flanigans Enterprises Inc
NYSE MKT:BDL
|
0.062x |
|
Anson Resources Ltd
AU:ASN
|
-0.082x |
|
Schwälbchen Molkerei Jakob Berz AG
F:SMB
|
N/A |
|
OneConstruction Group Limited Ordinary Shares
NASDAQ:ONEG
|
-0.837x |
|
Yonyu Plastics Co Ltd
TW:1323
|
0.015x |
Annual Cash Flow Conversion Efficiency for Scilex Holding Company (2020–2024)
The table below shows the annual cash flow conversion efficiency of Scilex Holding Company from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see SCLX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-192.64 Million | $19.35 Million | -0.100x | -183.88% |
| 2023-12-31 | $-172.94 Million | $-20.71 Million | 0.120x | +120.41% |
| 2022-12-31 | $36.24 Million | $-21.26 Million | -0.587x | -558.16% |
| 2021-12-31 | $-223.88 Million | $-28.66 Million | 0.128x | -42.34% |
| 2020-12-31 | $-141.68 Million | $-31.46 Million | 0.222x | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more